Efficacy and safety of intra-vesical B.C.G in superficial bladder tumor after TURGB
Medical Forum Monthly. 2009; 20 (5): 12-16
Dans En
| IMEMR
| ID: emr-111297
Responsable en Bibliothèque :
EMRO
ABSTRACT
To determine the effectiveness, safety and side effects of intra-vesicle B.C.G immuno-therapy in superficial bladder tumor after TURGB. Observational study / Quasi-experimental. Bolan Medical College Teaching Hospital Quetta, from August, 2004 to July, 2008. Patients age ranges from 40 to 75 years.21 males and 4 females, with proven superficial bladder tumor [Ta-Tl]were included after TURGB in this study. These 25 patients underwent intra-vesicle immunotherapy [BCG.].These patients were followed up for two years and extent of improvement in presenting symptoms, recurrence of tumor, side effects and complications were noted. Out of 25 patients 23 patients [92%] received BCG immunotherapy after TURGB. Out of these 23 Patients 15 patient [65.2%] showed complete response and 6 patients [26.08%] showed partial response while remaining 2 patients [8.69%] had constant progression in disease and underwent cystectomy. It was concluded that B.C.G immunotherapy is very effective and save patients from recurrence and cystectomy
Recherche sur Google
Indice:
IMEMR
Sujet Principal:
Tumeurs de la vessie urinaire
/
Administration par voie vésicale
/
Études prospectives
/
Traitement médicamenteux
/
Immunothérapie
Limites du sujet:
Female
/
Humans
/
Male
langue:
En
Texte intégral:
Med. Forum Mon.
Année:
2009